Search All Jobs

Showing 2 of 2 Jobs

Night Lead - Sunday - Wednesday

$25.46/hr

Omaha, NE, USA

Night Lead

$25.46/hr

Coralville, IA, USA

Full-Time

Night Lead

Sunday, Wednesday

Confirmed live in the last 24 hours

American Cancer Society

American Cancer Society

5,001-10,000 employees

Advocacy, research, and patient support for cancer

Compensation Overview

$25.46/hr

Junior, Mid

Omaha, NE, USA

Category
Security & Protective Services
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a American Cancer Society referral from your network.

đź’ˇ

Applications through a referral are 3x more likely to get an interview!

Requirements
  • High school diploma or equivalent; additional education or training in hospitality management, security, or related field preferred.
  • Minimum 1 year experience in hotel, hospitality, healthcare or a related field, with knowledge of overnight operations, guest services, and night auditing procedures.
  • Excellent communication and interpersonal skills, with the ability to interact effectively with guests, staff, and stakeholders from diverse backgrounds and handle sensitive or challenging situations with professionalism and empathy.
  • Knowledge of security procedures, emergency response protocols, and safety regulations, with the ability to manage emergencies and crisis situations effectively and ensure the safety and security of guests and staff.
  • Ability to work independently and make sound decisions under pressure, demonstrating resourcefulness, adaptability, and problem-solving skills in a fast-paced and dynamic environment.
  • Availability to work overnight shifts, including weekends and holidays, with flexibility to respond to emergencies or unexpected situations as needed.
Responsibilities
  • Address guest inquiries, concerns, and requests during overnight hours, providing assistance, information, and support as needed to ensure a positive and comfortable experience for guests.
  • Implement and enforce security procedures and safety protocols to protect guests, staff, and property during overnight hours, conducting regular patrols and inspections to monitor for any potential risks or hazards.
  • Manage emergencies and crisis situations effectively, including medical emergencies, security incidents, and facility issues, coordinating response efforts and communicating with appropriate stakeholders as necessary.
  • Maintain open communication with internal departments, including program staff, administrative staff, and maintenance staff, as well as external stakeholders such as healthcare providers and emergency services, to coordinate efforts and address any issues or concerns that arise overnight.
  • Perform administrative duties such as completing nightly reports, updating guest records, and managing room inventory, ensuring accuracy and efficiency in all administrative tasks.
  • Conduct regular inspections of guest rooms and common areas to ensure cleanliness, maintenance, and compliance with Hope Lodge standards, addressing any deficiencies or issues promptly and appropriately.
  • Perform night auditing duties, including reconciling HMS, verifying Check In Data, and preparing reports, to ensure accuracy and compliance with HMS procedures.
  • Reset the lodge for the next day. Conduct regular housekeeping to ensure first impressions are maintained throughout the lodge. Launder all of the days linens and reset linen room for next day.
Desired Qualifications
  • Additional education or training in hospitality management, security, or related field preferred.
American Cancer Society

American Cancer Society

View

The American Cancer Society focuses on fighting cancer and improving the lives of those affected by it. They work through three main areas: advocacy, research, and patient support. Advocacy efforts aim to influence policies that benefit cancer patients and their families. Research initiatives are dedicated to finding new ways to prevent, detect, and treat cancer, contributing to advancements in medical knowledge. Patient support services provide resources and assistance to individuals and families dealing with cancer, ensuring they have access to the care they need. Unlike other organizations, the American Cancer Society uniquely combines these efforts to create a comprehensive approach to cancer care. Their ultimate goal is to end cancer for everyone, making sure that all individuals have the opportunity to prevent, detect, treat, and survive cancer.

Company Size

5,001-10,000

Company Stage

Series B

Total Funding

$2.7M

Headquarters

Atlanta, Georgia

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Besitos targets younger, tech-savvy audience for fundraising.
  • Multi-cancer early detection testing could lead to more funding for early initiatives.
  • Transportation grant improves patient adherence and outcomes in cancer treatment.

What critics are saying

  • Mobile gaming partnership may struggle to engage users effectively.
  • Transportation grant may not meet all patient needs, limiting program impact.
  • Focus on early detection may divert attention from traditional cancer research.

What makes American Cancer Society unique

  • American Cancer Society partners with Besitos for innovative mobile gaming fundraising.
  • Focus on multi-cancer early detection testing with GRAIL and Kate Walsh advocacy.
  • Grant to Cheyenne Regional Medical Center for patient transportation during cancer treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Paid Vacation

401(k) Retirement Plan

Wellness Program

Professional Development Budget

Company News

Forbes
May 13th, 2025
Tv Star Kate Walsh Talks About Multi-Cancer Early Detection Testing

Grey’s Anatomy star Kate Walsh discussed her parents experiences with cancer and her own cancer. More scare and the importance of detecting cancer early. (Photo: Courtesy of HelloMMC) Courtesy of HelloMMCGrey’s Anatomy star Kate Walsh called this decision a “no brainer” in both a serious and punny way. It’s her decision to team up with the company GRAIL to advocate for more multi-cancer early detection testing in a campaign they’re calling “Generation Possible.”What Is Multi-cancer Early Detection (MCED) Testing?Now MCED, short for multi-cancer early detection, isn’t exactly a term that’s already bandied about regularly like “OMG” or “IYKYK.” It’s a newer term that may at first sound quite technical. But breaking the term down to its component parts can help understand what it is. “Cancer" along with “early detection” means trying to catch cancer in its early stages before it’s spread and becomes much more difficult to treat

Cision
May 9th, 2025
Imfinzi Improved Dfs In Early Bladder Cancer

Imfinzi improved DFS in early bladder cancer

Cheyenne Regional Medical Center
May 6th, 2025
The American Cancer Society Awards 5K to The Cheyenne Regional Medical Center Foundation to Provide Transportation to Patients During Cancer Treatment

May 1, 2025 - The American Cancer Society has awarded a grant of $5,000 to the Cheyenne Regional Medical Center (CRMC) Foundation to provide transportation assistance for cancer patients undergoing treatment.

PharmiWeb
Apr 30th, 2025
Fixed-Duration Calquence-Based Regimens Recommended For Approval In The Eu By Chmp For 1St-Line Chronic Lymphocytic Leukaemia

Recommendation based on AMPLIFY Phase III trial which showed Calquencecombinations demonstrated statistically significant and clinically meaningfulimprovement in progression-free survival vs. chemoimmunotherapyA fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the AMPLIFY Phase III trial, which were presented at the American Society of Haematology (ASH) 2024 Annual Meeting and published in The New England Journal of Medicine.1Results showed Calquence plus venetoclax reduced the risk of disease progression or death by 35% compared to standard-of-care chemoimmunotherapy (investigator’s choice of fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab; hazard ratio [HR] 0.65; 95% confidence interval [CI] 0.49-0.87; p=0.0038). Calquence plus venetoclax with obinutuzumab demonstrated a 58% reduction in the risk of disease progression or death compared to standard-of-care chemoimmunotherapy (HR 0.42; 95% CI 0.30-0.59; p<0.0001).2At three years, 77% of patients treated with Calquence plus venetoclax and 83% of patients treated with Calquence plus venetoclax and obinutuzumab were progression free, versus 67% of patients treated with chemoimmunotherapy.1 Median progression-free survival (PFS) was not reached for either experimental arm versus 47.6 months for chemoimmunotherapy.1Wojciech Jurczak, MD, Maria Sklodowska-Curie National Institute of Oncology, Kraków, Poland and investigator for the trial, said: “Chronic lymphocytic leukaemia is an incurable cancer which means patients live with the disease and stay on treatment for many years, which can have long-term effects. The fixed-duration Calquence regimens will allow patients to take breaks from their treatment, reducing the risk of long-term adverse events and drug resistance.”Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “With this recommendation, Calquence plus venetoclax can potentially be the only all-oral second-generation BTK inhibitor option approved in Europe for patients with previously untreated chronic lymphocytic leukaemia. Calquence has demonstrated efficacy and safety in fixed-duration and treat-to-progression regimens providing patients and their doctors more treatment flexibility.”CLL is the most common type of leukaemia in adults, with an estimated 27,000 patients diagnosed in the UK, France, Germany, Spain and Italy in 2024.3The safety and tolerability of Calquence was consistent with its known safety profile, and no new safety signals were identified.Regulatory applications for Calquence plus venetoclax, with or without obinutuzumab, in this setting are currently under review in several countries based on the AMPLIFY results.NotesChronic lymphocytic leukaemia (CLL)CLL is the most prevalent type of leukaemia in adults, with over 117,000 new cases globally in 2021.4 Although some people with CLL may not experience any symptoms at diagnosis, others may experience symptoms, such as weakness, fatigue, weight loss, chills, fever, night sweats, swollen lymph nodes and abdominal pain.5 In CLL, there is an accumulation of abnormal lymphocytes within the blood, bone marrow and lymph nodes. As the number of abnormal cells increases, there is less room within the marrow for the production of normal white blood cells, red blood cells and platelets.6 This could result in infection, anaemia and bleeding

PR Newswire
Apr 29th, 2025
Bladder Cancer Presentations At Aua2025: Blue Light Cystoscopy Improves Risk Stratification And Informed Decision Making

OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management of the disease, improved risk stratification and therefore the ability of the BLC procedure to help urologists and patients make well-informed decisions. The American Urological Association Annual Congress 2025 was held April 26-28, at the Venetian Convention & Expo Center in Las Vegas, NV, USA.Three abstracts were presented from Photocure's U.S. Blue Light Cystoscopy with Cysview Registry, a large multicenter bladder cancer patient registry of real-world data, established by Photocure in 2014 and projected to enroll 4,400 patients. In addition, the study protocol of a randomized controlled non-inferiority trial comparing a multidisciplinary approach including PDD-guided primary TURBT to reduce the patients' burden of second resection including a total of 327 patients has been presented. This investigator-initiated trial is supported by Photocure.The abstract sessions on Saturday, April 26:"Upstaging and Risk Migration with BLC for NMIBC: Results from a prospective multicenter registry" by Alireza Ghoreifi, Duke UniversityThe study looked at 2,854 NMIBC* patients from the US Blue Light Cystoscopy with Cysview Registry. A total of 201 (7%) patients had at least one malignant lesion detected exclusively by BLC while having a negative WLC